The FDA has granted orphan drug designation (ODD) to LP-284, a next-generation acylfulvene small molecule, for the treatment ...

Project LiBRha aims to improve pediatric STS diagnosis and treatment through comprehensive molecular testing and liquid biopsy integration. The initiative involves 18 centers and partnerships with the ...

Kaposi's sarcoma (KS) is a low-grade vascular neoplasm mediated by the human herpesvirus-8. Only 1 clinical subtype, the endemic/African subtype, commonly affects the pediatric population. Although ...

Sixth overall for Lantern’s A.I.-driven precision oncology pipelineOrphan designation expands LP-284's potential for an ...

Actuate Therapeutics, Inc. has announced the completion of the Phase 1 study evaluating its drug elraglusib in pediatric patients with refractory malignancies, specifically Ewing Sarcoma (EWS). The ...

Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.

Rhabdomyosarcoma, a common form of soft tissue sarcoma in pediatric patients with outcomes that have improved through research, is rare among older patients, who also have significantly poorer ...

Leo Mascarenhas, MD, MS, has an important message for parents whose children have been diagnosed with sarcoma, a type of cancer that develops in the bones or soft tissues. "For many children, there ...

Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma Whole-Genome Profiling of Pediatric Diffuse ...

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...

CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...